Patients with EGFR expressing NSCLC benefit most from necitumumab added to chemotherapy

Posted by on April 15, 2016 12:15 pm
Tags:
Categories: health

Patients with epidermal growth factor receptor expressing advanced squamous non-small-cell lung cancer benefit most from necitumumab added to gemcitabine and cisplatin chemotherapy, according to a subgroup analysis from the SQUIRE trial.

Leave a Reply

Your email address will not be published.